A new coronavirus research project has the potential to improve our understanding of the effectiveness of vaccines against dangerous virus variants.
NSW will invest more than $ 4.5 million in a new project to investigate the health effects of coronavirus vaccination.
Chief Health Officer Kelly Chant said the state is well suited to the global situation to investigate the effects of the new vaccine, as most of the population is not infected with the coronavirus.
“As vaccination is on track, this surveillance and real-world study continues to provide timely and robust data to the people of NSW to ensure the best results, and we It helps us navigate the way we should go, “Dr. Chant said in a statement.
“It puts us in a strong position and informs us about new issues and opportunities, and vaccine policies that can address future developments and trials of next-generation vaccines.
“We continue to learn through this pandemic, and this study can advise on immunization schedules, including the potential need for additional vaccinations for vulnerable groups and the wider community. “
The Vaccine, Infection and Immunology Collaborative Research Group (VIIM) will be funded by the state government for three years.
The experts that make up the group come from several different universities, hospitals, research institutes and government agencies.
The University of NSW, NSW Health Pathology, and the Sydney Children’s Hospital Network are one of the institutions contributing to the project.
The funds will be drawn from the previously announced $ 25 million coronavirus research fund by the government.
“This study also establishes a valuable biobank of specimens, which is essential for current and future studies to keep people in NSW healthy and protected from infectious diseases,” said Dr. Chant. I am.
Initially issued as follows How Australia Solves the Vaccine Mystery
NSW will invest $ 4.5 million to study the effectiveness of the coronavirus vaccine
Source link NSW will invest $ 4.5 million to study the effectiveness of the coronavirus vaccine